Today: 8 June 2026
Browse Category

NASDAQ:BHVN 14 August 2025 - 5 November 2025

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven Ltd. shares plunged about 40% on Nov. 5, 2025, after the FDA rejected its lead drug VYGLXIA for spinocerebellar ataxia, citing trial design and data issues. The company will cut R&D spending by 60% and halt non-priority programs. Analysts downgraded the stock, which now trades near $8–9, down over 70% year-over-year. Biohaven reported a $198 million net loss in Q2 with $408 million in cash.
5 November 2025
·
Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

The FDA approved Insmed’s brensocatib as the first therapy for non-cystic fibrosis bronchiectasis, following positive results in a 1,700-patient trial. Novartis reported Phase 3 successes for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. In China, RemeGen’s telitacicept met its main goal in a Phase 3 Sjögren’s trial. Response Pharmaceuticals’ RDX-002 showed weight-loss maintenance in post-GLP-1 patients.
14 August 2025
···

Stock Market Today

  • Traders Price SpaceX Synthetic IPO Contracts 70% Above $135 Pricing Ahead of June 12 Nasdaq Debut
    June 8, 2026, 5:10 PM EDT. SpaceX's upcoming IPO on Nasdaq scheduled for June 12 has attracted crypto traders, who are trading synthetic perpetual futures reflecting the company's valuation on decentralized exchange Hyperliquid. The Hyperliquid SPCX-USDC contract, launched on May 17, briefly surged to $230, about 70% above the $135 IPO price, before easing to around $165, still 22% above the official offering. These synthetic contracts allow speculation on SpaceX's value with no ownership rights or voting power, settled in USDC stablecoin. This market provides real-time, retail-accessible pre-IPO price signals. Similar behavior was seen ahead of Cerebras' IPO, where pre-IPO contract prices also exceeded the official offering.

Latest articles

IonQ Jumps as Quantum IPO Rush Sets Wall Street Benchmark

IonQ Jumps as Quantum IPO Rush Sets Wall Street Benchmark

8 June 2026
IonQ surged 10.5% to $62.77, outpacing quantum peers after Quantinuum’s $1.68 billion Nasdaq IPO gave investors a new benchmark for trapped-ion quantum stocks; IonQ’s rally follows its May guidance raise and soaring revenue, but losses and a long commercialization timeline remain key risks.
Snap Shares Climb as Debt Markets Send Signal

Snap Drops Again as Wall Street Stays Wary

8 June 2026
Snap plunged 2.1% to $5.64, underperforming a tech rebound, as investors weighed improved cash flow and a recent S&P credit upgrade against ongoing ad-market pressure, cost cuts, and spending on Specs; the stock’s weakness stood out as peers like Pinterest gained, highlighting market doubts about Snap’s ability to sustain growth amid tough competition and uncertain ad budgets.
Dow Drops After Hours, AI Rally Sidesteps Blue Chips

Dow Drops After Hours, AI Rally Sidesteps Blue Chips

8 June 2026
The Dow Jones fell 104.70 points, or 0.21%, to 50,762.08 as tech and chip stocks rebounded sharply, with the Philadelphia SE Semiconductor Index up 6.2% after Friday’s $1 trillion selloff; Apple dropped 1.4% despite its AI event, and investors now await Wednesday’s inflation data and Middle East energy risks as the next key tests for the market’s fragile rebound.
Nasdaq rises as AI names find support after market selloff

Nasdaq rises as AI names find support after market selloff

8 June 2026
Nasdaq surged 1.27% as investors snapped up AI and chip stocks after Friday’s rout, with the Philadelphia Semiconductor Index jumping 6.2%; Citigroup hiked its S&P 500 year-end target to 8,100 on AI demand, but Goldman Sachs warned strong jobs data makes a Fed rate hike more plausible, posing risks to growth stocks if inflation surprises.
Go toTop